Table 1 Outcome measures of the trial

Primary outcome measure

1A

Plasmodium spp. infection diagnosed by RDT [Change in the prevalence of Plasmodium spp. infections detected by RDT per week per village]

RDT

Assessed weekly, longitudinally over 12 months

Secondary outcome measures

2A

Symptomatic malaria diagnosed by RDT [Change in the prevalence of symptomatic Plasmodium spp. infections detected by RDT per week per village]

RDT and Malaria register

Assessed weekly, longitudinally over 12 months

2B

Plasmodium spp. infection as determined by polymerase chain reaction (PCR) [Change in the prevalence of Plasmodium spp. infection as determined by PCR from RDT cassette samples and dried blood spot (DBS) samples]

PCR

Assessed weekly, longitudinally over 12 months

2C

Plasmodium spp. infections with drug resistance mutations [Change in the prevalence of Plasmodium spp. infection with drug resistance mutations]

PCR

Assessed weekly, longitudinally over 12 months

2D

Prevalence of antibodies to Plasmodium spp. [Prevalence of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples]

ELISA

Assessed weekly, longitudinally over 12 months

2E

Levels of antibodies to Plasmodium spp. [Levels of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples]

ELISA

Assessed weekly, longitudinally over 12 months

2F

Prevalence of antibodies to vector salivary antigens [Levels of antibody biomarkers of vector exposure]

ELISA

Assessed weekly, longitudinally over 12 months

2G

Levels of antibodies to vector salivary antigens [Levels of antibody biomarkers of vector exposure]

ELISA

Assessed weekly, longitudinally over 12 months